Pilot 1
Study of Genomics and Epigenomics Markers for Early Risk Assessment of Pancreatic Cancer
Pilot 1: The objective of this pilot is to (i) provide individuals with information about risk factors for future disease; (ii) raise awareness of health conditions and educate individuals on how to prevent life threatening diseases like Pancreatic Cancer.
Pilot 2
Interventional Monocentric Study based on Patient-Reported Outcomes
This pilot study in iHelp is aimed at the definition of personalised therapeutic strategies that can maximize their efficacy and reduce the risks of side-effects in patients affected by Pancreatic Cancer, and significantly improve Quality of Life (QoL) of high-risk individuals.
Pilot 3
Study of Lifestyle Choices on Elevating the Risk Factors for Pancreatic Cancer
The pilot will be focused on studying the effects of lifestyle choices on the risks associated with Pancreatic Cancer, the development of new targeted prevention and intervention measures, and the ability to trace risk based on the analysis of multiple health-related parameters; and using this knowledge in the design of new interventions and treatments of individualization will offer new opportunities for not only clinicians but also to individuals who can better manage their health.
Pilot 4
Study of Risk, Personalised Recommendations and Measures to Raise Awareness of Relevant Factors
The iHelp initiative will influence the design of strategies for the early detection of neoplasia, which is when we can best deal with therapeutic intervention, as well as in the genomic study of neoplasia, the application and development of new diagnostic techniques, and therapeutic optimization through the combination of all the information collected during the duration of the study.
Pilot 5
Study of Improved Risk Prediction Models and Targeted Interventions that can Delay the Onset of Cancer
Will conduct study in three phases. (1) Applying machine learning algorithms to predict high risk individuals towards pancreatic cancer for early stage management of the disease, (2) piloting of mobile applications and monitoring via wearable devices for personalized healthcare and improved Quality of Life, (3) evaluation of the second phase through diagnostic tests for Pancreatic Cancer.